Kiadis Pharma NV’s takeover last year of Cytosen Therapeutics Inc. to get a natural killer (NK) platform paid off in a potentially huge way, with Sanofi SA paying €17.5 million (US$19.7 million) up front in a licensing deal with as much as €857.5 million more if preclinical, clinical, regulatory and commercial goals are reached, as well as up to double-digit royalties.
Missing the primary endpoint along with key secondary endpoints in a phase III trial of Kevzara (sarilumab), an interleukin-6 (IL-6) receptor antibody, for treating COVID-19 patients who need mechanical ventilation caused Regeneron Pharmaceuticals Inc. and Sanofi SA to halt the study.
The FDA Thursday approved Mylan NV’s Semglee (insulin glargine), adding another player to the U.S. insulin space that has been pretty much controlled by three companies – Eli Lilly and Co., Novo Nordisk A/S and Sanofi SA.
Threads of hope and caution stitched together a wide-ranging appraisal of COVID-19 vaccines at June 9's BIO Digital plenary, "A Way Forward." The good news, delivered by one of the world's most sober participants in the pandemic response, mercifully came first.
Blue chip public biopharmaceutical companies continued their positive trajectory in May, with the BioWorld Biopharmaceutical index recording an 8% jump in valuation and contributing to its year-to-date performance of approximately 17%.
LONDON – Geopolitical tensions over the issue of access to COVID-19 vaccines intensified this week, after the CEO of French pharmaceutical company Sanofi SA said the U.S. government would get first access to its product because it was first to fund the research.
CAJICA, Colombia – Previous research to develop vaccines for dengue and Zika virus could become the cornerstone for a vaccine against COVID-19, which the Autonomous University of Mexico (UNAM) is working on.